SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)

被引:0
作者
A. de Juan Ferré
R. Álvarez Álvarez
A. Casado Herráez
J. Cruz Jurado
A. Estival González
J. Martín-Broto
V. Martínez Marín
A. Moreno Vega
A. Sebio García
C. Valverde Morales
机构
[1] Hospital Universitario Marqués de Valdecilla,
[2] Hospital General Universitario Gregorio Marañón,undefined
[3] Hospital Universitario Clínico San Carlos,undefined
[4] Hospital Universitario de Canarias,undefined
[5] Institut Català d’Oncologia-Badalona,undefined
[6] Hospital Universitario Virgen del Rocío,undefined
[7] Hospital Universitario la Paz,undefined
[8] Hospital Universitario Reina Sofía,undefined
[9] Hospital de la Santa Creu I Sant Pau,undefined
[10] Hospital Universitario Vall d’Hebron,undefined
来源
Clinical and Translational Oncology | 2021年 / 23卷
关键词
Sarcoma; Guidelines; Soft-tissue tumors; Uncommon tumors;
D O I
暂无
中图分类号
学科分类号
摘要
Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed.
引用
收藏
页码:922 / 930
页数:8
相关论文
共 119 条
[1]  
Dykewicz CA(2001)Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients Clin Infect Dis 33 139-144
[2]  
Deroose JP(2011)Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas J Clin Oncol 29 4036-4044
[3]  
Eggermont AM(2014)Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial Ann Surg Oncol 21 2484-2489
[4]  
van Geel AN(2001)Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial J Clin Oncol 19 1238-1247
[5]  
Burger JW(2008)A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma Cancer 113 573-581
[6]  
den Bakker MA(2016)Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group Ann Oncol 27 2283-2288
[7]  
de Wilt JH(2013)Multimodality therapy for advanced or metastatic sarcoma Curr Probl Cancer 37 74-86
[8]  
Beane JD(2018)Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma Radiol Med 123 871-878
[9]  
Yang JC(2014)Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Lancet Oncol 15 415-423
[10]  
White D(2012)Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome Ann Oncol 23 517-523